Literature DB >> 22674976

Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus.

Christopher D O'Donnell1, Amber Wright, Leatrice N Vogel, Chih-Jen Wei, Gary J Nabel, Kanta Subbarao.   

Abstract

Compared to seasonal influenza viruses, the 2009 pandemic H1N1 (pH1N1) virus caused greater morbidity and mortality in children and young adults. People over 60 years of age showed a higher prevalence of cross-reactive pH1N1 antibodies, suggesting that they were previously exposed to an influenza virus or vaccine that was antigenically related to the pH1N1 virus. To define the basis for this cross-reactivity, ferrets were infected with H1N1 viruses of variable antigenic distance that circulated during different decades from the 1930s (Alaska/35), 1940s (Fort Monmouth/47), 1950s (Fort Warren/50), and 1990s (New Caledonia/99) and challenged with 2009 pH1N1 virus 6 weeks later. Ferrets primed with the homologous CA/09 or New Jersey/76 (NJ/76) virus served as a positive control, while the negative control was an influenza B virus that should not cross-protect against influenza A virus infection. Significant protection against challenge virus replication in the respiratory tract was observed in ferrets primed with AK/35, FM/47, and NJ/76; FW/50-primed ferrets showed reduced protection, and NC/99-primed ferrets were not protected. The hemagglutinins (HAs) of AK/35, FM/47, and FW/50 differ in the presence of glycosylation sites. We found that the loss of protective efficacy observed with FW/50 was associated with the presence of a specific glycosylation site. Our results suggest that changes in the HA occurred between 1947 and 1950, such that prior infection could no longer protect against 2009 pH1N1 infection. This provides a mechanistic understanding of the nature of serological cross-protection observed in people over 60 years of age during the 2009 H1N1 pandemic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674976      PMCID: PMC3421718          DOI: 10.1128/JVI.00147-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

2.  Heterotypic protective immune reactions in mice infected with distinct serotypes of human influenza virus.

Authors:  F Floc'h; G H Werner
Journal:  Ann Microbiol (Paris)       Date:  1978 May-Jun

3.  Antigenic similarity of influenza A (H1N1) viruses from epidemics in 1977--1978 to "Scandinavian" strains isolated in epidemics of 1950--1951.

Authors:  A P Kendal; G R Noble; J J Skehel; W R Dowdle
Journal:  Virology       Date:  1978-09       Impact factor: 3.616

Review 4.  Immunity to influenza in man.

Authors:  R B Couch; J A Kasel
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

5.  Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus.

Authors:  D B Burlington; M L Clements; G Meiklejohn; M Phelan; B R Murphy
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

6.  Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.

Authors:  Chih-Jen Wei; Jeffrey C Boyington; Kaifan Dai; Katherine V Houser; Melissa B Pearce; Wing-Pui Kong; Zhi-Yong Yang; Terrence M Tumpey; Gary J Nabel
Journal:  Sci Transl Med       Date:  2010-03-24       Impact factor: 17.956

7.  Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule.

Authors:  Emi Tsuchiya; Kanetsu Sugawara; Seiji Hongo; Yoko Matsuzaki; Yasushi Muraki; Zhu-Nan Li; Kiyoto Nakamura
Journal:  J Gen Virol       Date:  2002-05       Impact factor: 3.891

Review 8.  An overview of serum antibody responses to influenza virus antigens.

Authors:  R B Couch
Journal:  Dev Biol (Basel)       Date:  2003

9.  A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.

Authors:  Ellen Z Baum; Pamela C Wagaman; Linh Ly; Ignatius Turchi; Jianhua Le; Doris Bucher; Karen Bush
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

10.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

View more
  22 in total

1.  A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Authors:  Mariana Baz; Myeisha Paskel; Yumiko Matsuoka; James R Zengel; Xing Cheng; John J Treanor; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.

Authors:  Ted M Ross; Chyongchiou Jeng Lin; Mary Patricia Nowalk; Hsin-Hui Huang; Sarah M Spencer; David K Shay; Suryaprakash Sambhara; Maria E Sundaram; Thomas Friedrich; Sandy Sauereisen; Chalise E Bloom; Richard K Zimmerman
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

3.  A case report of a patient in whom antibodies against the 2009 pandemic influenza A/H1N1 virus have been present since June 1999.

Authors:  Masashi Yoshida; Hirotoshi Sugino; Tadashi Iizuka; Liu Xiaofang; Akira Suzuki; Hitoshi Oshitani; Tatsuo Suzutani; Kazufumi Ikuta
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

4.  Impaired heterologous immunity in aged ferrets during sequential influenza A H1N1 infection.

Authors:  Stéphane G Paquette; Stephen S H Huang; David Banner; Luoling Xu; Alberto Leόn; Alyson A Kelvin; David J Kelvin
Journal:  Virology       Date:  2014-08-01       Impact factor: 3.616

5.  Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus.

Authors:  Donald M Carter; Chalise E Bloom; Eduardo J M Nascimento; Ernesto T A Marques; Jodi K Craigo; Joshua L Cherry; David J Lipman; Ted M Ross
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

6.  Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.

Authors:  Sinthujan Jegaskanda; Jason T Weinfurter; Thomas C Friedrich; Stephen J Kent
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

7.  B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Authors:  Mark Y Sangster; Jane Baer; Felix W Santiago; Theresa Fitzgerald; Natalia A Ilyushina; Aarthi Sundararajan; Alicia D Henn; Florian Krammer; Hongmei Yang; Catherine J Luke; Martin S Zand; Peter F Wright; John J Treanor; David J Topham; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2013-04-10

8.  Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.

Authors:  Christopher D O'Donnell; Amber Wright; Leatrice Vogel; Kobporn Boonnak; John J Treanor; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

9.  The antigenic evolution of influenza: drift or thrift?

Authors:  Paul S Wikramaratna; Michi Sandeman; Mario Recker; Sunetra Gupta
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-04       Impact factor: 6.237

10.  Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure.

Authors:  Stephen S H Huang; Zhen Lin; David Banner; Alberto J León; Stéphane G Paquette; Barry Rubin; Salvatore Rubino; Yi Guan; David J Kelvin; Alyson A Kelvin
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.